Core Insights - JD Health has formed a deep collaboration with local innovative pharmaceutical company Kaiqi Xincheng Biopharmaceutical Technology Co., Ltd. to support the clinical cure of chronic hepatitis B patients in China [1][2] - The collaboration will leverage JD Health's strengths in medical services and instant retail, launching two innovative drugs: the first-class drug Adefovir Dipivoxil Tablets (brand name: Xinshumu®) and a zinc-selenium multivitamin soft capsule (brand name: Kaimumu®) [1][2] Drug Launch Details - Adefovir Dipivoxil Tablets (Xinshumu®) are designed for the treatment of adult chronic hepatitis B and have received support from national major new drug creation technology projects during the "12th Five-Year" and "13th Five-Year" plans [1] - Clinical trial results indicate that the drug effectively and persistently inhibits the virus, with a significantly higher proportion of patients achieving HBsAg levels below 1000 IU/mL compared to the control group (P<0.05) and other similar drugs [1] - The zinc-selenium multivitamin soft capsule (Kaimumu®) is formulated for liver nutrition and is rich in nine vitamins and two minerals, designed for easy absorption and convenient daily use [2] Service Integration - JD Health will utilize its ecosystem of "online consultation + pharmaceutical retail + instant delivery" to create a service loop that includes professional supply, online specialist guidance, and rapid delivery, facilitating the widespread availability of the new drugs [2] - Patients can purchase these new drugs through the JD APP or JD pharmacies nationwide with a valid prescription starting immediately [2] Strategic Goals - JD Health aims to enhance the overall efficiency and quality of the pharmaceutical supply chain through ongoing strategic collaboration with Kaiqi Xincheng, optimizing the patient experience [2] - The company is committed to providing high-quality pharmaceutical health products and services, contributing to the "Healthy China 2030" strategic goals by improving the accessibility of innovative drugs [3]

Market Overview - The A-share market showed mixed performance on January 8, with the Sci-Tech 50 Index rising by 1.77% and a half-day trading volume of 1.77 trillion, down by 701 billion from the previous trading day [1] - The Shanghai Composite Index increased by 0.09%, while the Shenzhen Component Index and the ChiNext Index fell by 0.2% and 0.52%, respectively [1] - Huachuang Securities believes the market is not extremely overheated, with trading volume and turnover rates indicating room for growth [1] Key Sectors Controlled Nuclear Fusion - The controlled nuclear fusion sector continued to show strength, with companies like China Nuclear Engineering and others achieving consecutive gains [3] - CITIC Securities noted that breakthroughs in high-temperature superconductors and AI technology are driving investment in large scientific facilities, creating significant opportunities in the upstream segment of the industry [3] Commercial Aerospace - The commercial aerospace sector experienced repeated strength, with companies such as Galaxy Electronics and others hitting their daily price limits [4] - Zhongtai Securities indicated that the commercial aerospace industry is entering a new phase of rapid development, with upcoming catalysts expected to enhance investment opportunities [4] Computing Power Chips - The computing power chip sector saw gains, with companies like Haiguang Information rising over 10% [5] - The Ministry of Industry and Information Technology, along with other departments, issued guidelines to strengthen AI computing power supply, promoting the development of intelligent chips and related technologies [5] Institutional Insights - CITIC Securities predicts a higher probability of upward market fluctuations in 2026, emphasizing the need for a balance between external and internal demand [7] - Zhongtai Securities maintains a cautiously optimistic view on the technology sector, suggesting that investors focus on specific sub-sectors with strong fundamentals [8] - Everbright Securities warns of increased market volatility due to profit-taking pressures, advising caution in investment strategies [9]

2026年1月7日，"踏浪前行 做多中国——全球重构下的中国资产机遇"华西证券2026年资本市场投资与产业年会在成都召开，华西证券党委副 书记、总裁杨炯洋致开幕辞，多位在蓉高管共同出席本次会议。 杨炯洋在致辞中向出席本次会议的嘉宾表示热烈欢迎。他指出，在全球格局深度重塑、"十五五"谋篇启章的关键阶段，"做多中国"需要坚定 的信念，更离不开成熟完备的资本市场和坚实的金融力量。本次会议以"踏浪前行 做多中国——全球重构下的中国资产机遇"为主题，力求以 长远视角挖掘中国资产价值，以开放姿态拥抱新发展格局，以专业力量助推资本市场高质量发展。他表示，作为一家专业的资本市场中介机 构、上市公司，华西证券积极响应国家战略部署，坚定推进"差异化发展、特色化经营"发展策略，致力于为客户提供定制化、全方位、全生 命周期的综合金融支持，助力企业客户把握区域一体化机遇深化发展。 杨炯洋向与会嘉宾介绍了华西证券业务布局。长期以来，公司聚焦"卖方研究、价值发现"，建立了一支具有较强品牌影响力和市场号召力的 卖方研究队伍，以及聚焦新一代信息技术、新材料、新消费、装备制造、医药健康五大方向的产业研究团队。华西证券实现了以直接股权投 资、定增 ...

财信证券认为，短期内，随着大盘震荡分化，连续普涨快涨行情或暂告一段落，指数层面震荡向上、题 材板块轮动的结构性行情大概率再度成为市场主基调，建议投资者采取去弱留强策略，逐步聚焦主线板 块，把握好轮动节奏。往后看，在海外经济仍有韧性、美元流动性大概率持续宽松、国内政策"双宽 松"基调延续、"反内卷"持续提振物价预期下，预计A股牛市仍将延续。 盘面上看，券商、保险、银行、酿酒等板块走低，军工、地产、医药、半导体等板块上扬，工业软件、 可控核聚变、商业航天概念等活跃。 8日早盘，沪指盘中窄幅震荡，科创50指数大涨近2%，全A股超3700股飘红。 截至午间收盘，沪指微涨0.09%报4089.45点，深证成指跌0.2%，创业板指跌0.52%，科创50指数涨 1.77%，沪深北三市合计成交约1.78万亿元。 （文章来源：证券时报网） ...

Group 1 - Notable fund managers have disclosed their latest stock adjustments as the new year begins, with several companies announcing related updates [1] - Fund managers Ge Lan and Tang Xiaobin reduced their holdings in Kelun Pharmaceutical (002422), while Zhao Bei increased her stake [1][2] - Liu Yanchun and Hu Xinwei reduced their holdings in Proya (603605), while Zhou Yun entered the top ten shareholders of Jiazhe New Energy (601619) [1][6] Group 2 - As of December 31, 2025, Ge Lan's fund held 38.1954 million shares of Kelun Pharmaceutical, having reduced by 1.867 million shares compared to the previous quarter [2] - Tang Xiaobin's fund exited the top ten shareholders of Kelun Pharmaceutical by the end of 2025, having reduced holdings from 24.2335 million shares to 13.94 million shares [4] - Zhao Bei's fund increased its holdings in Kelun Pharmaceutical to 22 million shares, up by 2 million shares from the previous quarter [4] Group 3 - Liu Yanchun's fund held 2.6 million shares of Proya as of December 30, 2025, down from 3.332 million shares, indicating a reduction of over 700,000 shares [7] - Hu Xinwei's fund is no longer among the top ten shareholders of Proya [8] - Zhou Yun's fund and the National Social Security Fund 404 combination entered the top ten shareholders of Jiazhe New Energy in the fourth quarter of 2025 [9] Group 4 - The National Social Security Fund 114 combination increased its holdings in Nanshan Aluminum (600219) by 4.3432 million shares in the fourth quarter of 2025 [9] - By the end of 2025, five ETF products were included among the top ten shareholders of Nanshan Aluminum, indicating the growing influence of index funds [9] Group 5 - A significant increase in institutional research activities has been noted, with over 10,000 research sessions conducted in the past month, focusing on sectors such as semiconductors, general equipment, automotive, and artificial intelligence [10] - Fund managers are optimistic about the performance of non-financial listed companies in A-shares for 2025 and 2026, anticipating a stable recovery [10]

Group 1 - Lu Yan Pharmaceutical has achieved 8 consecutive limit-up trading days within 15 days, indicating strong market interest [1] - The stock reached a trading limit at 11:11 AM today with a transaction volume of 1.694 billion yuan and a turnover rate of 16.86% [1] - The recent fluctuations in the brain-computer interface sector have attracted market attention, with financing dynamics in related fields contributing to this interest [1] Group 2 - Lu Yan Pharmaceutical has acknowledged the importance of artificial intelligence and big data in the medical and pharmaceutical fields, indicating ongoing research and exploration in these areas [1] - The recent performance of the stock may be influenced by these technological advancements and their applications in the healthcare sector [1] - Investors are advised to be cautious of the volatility associated with consecutive limit-up stocks and to engage in rational investment practices [1]

截至本周，已有25地发布2025年版医保及商保目录执行文件、22地明确召开药事会时间。该行建议持续 关注医保新纳入品种/适应症后续销售放量情况，以及商保的实际执行及支付情况。新年伊始，港股医 药板块表现亮眼，下周JPM行业大会召开在即，有望进一步催化板块行情。 该行认为，2026年板块稳中向好态势延续，后续选股逻辑或将重回基本面和估值，关注存在基本面预期 差、当前仍被低估、安全边际较大的头部个股。 智通财经APP获悉，交银国际发布研报称，2025年10月至今，内资通过港股通持有医药股的比例在小幅 下降后逐渐企稳，外资持仓整体平稳，内外资加大创新药布局的大方向不变。 ...

Market Overview - The A-share market experienced a slight increase on Wednesday, with the Shanghai Composite Index rising by 0.05% to close at 4085.77 points, and the Shenzhen Component Index increasing by 0.06% [1][7] - The total trading volume in the Shanghai and Shenzhen markets reached 2.85 trillion yuan [1][7] - In terms of industry performance, coal, electronics, and telecommunications sectors led the gains, while oil and petrochemicals, non-bank financials, and beauty care sectors lagged [1][7] - Concept sectors such as photoresists, newly listed technology stocks, and storage chips saw increases, while DRG, internet insurance, and brain-computer interface sectors declined [1][7] - The Hong Kong market saw the Hang Seng Index drop by 0.94% to 26458.95 points, and the Hang Seng Tech Index fell by 1.49% [1][7] Important News - The Ministry of Industry and Information Technology and eight other departments issued the "Implementation Opinions on the Special Action of 'Artificial Intelligence + Manufacturing'", aiming for key AI technologies to achieve reliable supply by 2027, with a focus on high-level intelligent computing infrastructure [2][8] - The State Administration for Market Regulation and the National Internet Information Office jointly released the "Supervision and Management Measures for Live E-commerce", targeting issues such as false marketing and counterfeit products in the live e-commerce sector [2][8] Industry Insights - In 2025, the FDA approved 46 new drugs, marking a decline in the number of approvals compared to 2024 and 2023, but the types of approved drugs were diverse and highly innovative [9][10] - The majority of the new drugs approved by the FDA in 2025 were focused on oncology, covering various solid tumors and hematological malignancies, with 34 new drugs undergoing special review processes [10] - Major multinational pharmaceutical companies led in new drug approvals, with notable approvals from Merck, Eli Lilly, Boehringer Ingelheim, and GlaxoSmithKline, while domestic companies like Zhongshan Kanfang Biopharmaceutical and Jiangsu Dize Pharmaceutical also received FDA approvals [10] - Investment recommendations suggest focusing on cutting-edge technology platforms, particularly those with ADC, siRNA, and cell gene therapy capabilities, and companies with global competitive research pipelines [10][12]

Core Insights - The modernization of industry is identified as the most crucial foundation and core of a modern industrial system, with a focus on strengthening the real economy and promoting technological innovation and digital transformation across various regions [1] Group 1: Industrial Development and Innovation - The Ministry of Industry and Information Technology (MIIT) has been advancing new industrialization since the 14th Five-Year Plan, enhancing the overall strength, quality, efficiency, innovation, competitiveness, and risk resistance of the industry [1] - Significant achievements have been made in various sectors, including integrated circuits, biomedicine, and AI-driven manufacturing, with a focus on creating a modern industrial system centered around advanced manufacturing [2] - The number of specialized and innovative small and medium-sized enterprises has increased from less than 40,000 to over 140,000 during the 14th Five-Year Plan, while "little giant" enterprises have grown from over 5,000 to 17,600 [3] Group 2: Industrial Clusters and Ecosystems - Industrial clusters are essential for high-quality development and transformation of manufacturing enterprises, with efforts to create specialized parks and ecosystems to enhance resource allocation and innovation collaboration [4] - The Hunan Medical Device Industrial Park serves as a successful example of rapid growth in the medical device sector, achieving explosive growth in just four years by attracting various upstream and downstream enterprises [4] Group 3: Digital Transformation - Traditional industries such as steel and machinery are accelerating their digital transformation, with companies like Shandong Haihua Group leveraging AI to enhance operational efficiency and safety [7] - The MIIT is implementing a digital transformation action plan for the manufacturing sector, establishing 62 digital transformation promotion centers and over 230 exemplary smart factories [9] - The next steps include further advancing the construction of a modern industrial system centered on advanced manufacturing and promoting industrial upgrades [9]

Core Insights - Beijing Economic-Technological Development Area (BDA) is launching a global opportunity list for 2026, focusing on strategic emerging industries and future industries, with 25 innovative application scenarios and 83 high-energy innovation spaces [1] Group 1: Innovation Spaces - BDA will open 83 high-energy innovation spaces covering biotechnology, health, robotics, new-generation information technology, and modern services, with a total area of approximately 5 million square meters [2] - The International Pharmaceutical Innovation Park is being developed as a national-level platform to facilitate efficient links from R&D to industrialization [2] - The first commercial aerospace research and production base in China, located on Rocket Street, will focus on the entire commercial aerospace industry chain [2] Group 2: Application Scenarios - BDA plans to open high-value application scenarios in six fields: information technology, biomedicine, robotics, new energy, digital economy, and smart cities, with a total of 25 innovative application scenarios [3] - In biomedicine, BDA encourages collaboration among top universities, medical institutions, and leading enterprises to build a world-class application base for life and health [3] - In robotics, BDA supports the development of smart hotels and elderly care stations that utilize robots in real environments [3] Group 3: Funding Support - BDA has established a fund ecosystem that includes a government investment guidance fund with a total scale of 20 billion yuan, focusing on new-generation information technology and future industries [4] - The fund ecosystem aims to cover the entire lifecycle of enterprises, having already influenced over 100 projects to attract more social capital [4] - BDA is collaborating with various financial institutions to create a total of 310 billion yuan in AIC funds to encourage early and small investments in technology [4]